Latest Breaking News On - Prnewswire johnson - Page 1 : comparemela.com

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program

United statesPrnewswire johnsonNatashab leighlNone of janssen research developmentJanssen research developmentJanssen biotech incPrincess margaret cancer centreAmerican society of clinical oncologyExchange commissionEuropean medicines agencyClinical oncologyAnnual meetingBiologics license applicationNew drug applicationPriority reviewPractice guidelines

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesNatashab leighlPrnewswire johnsonJanssen biotech incNone of janssen research developmentAmerican society of clinical oncology annual meetingEuropean medicines agencyAmerican lung associationNational cancer instituteWorld health organizationAmerican cancer societyAmerican society of clinical oncologyJanssen research developmentNational comprehensive cancer network incExchange commissionPrincess margaret cancer centre

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
cadillacnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cadillacnews.com Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaUnited statesSan antonioAnia diantonioRodriguez fabaSabine brookmanPrnewswire johnsonIndianj urolNone of janssen research developmentAmerican cancer societyLate development oncologyJanssen research developmentBladder cancer advocacy networkJanssen biotech incDrug administrationJanssen pharmaceuticals

TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

/PRNewswire/ Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of.

San antonioUnited statesComunidad autonoma de catalunaPrnewswire johnsonSabine brookmanRodriguez fabaAnia diantonioIndianj urolAmerican cancer societyAmerican urological associationJanssen pharmaceuticalsJanssen research developmentDrug administrationAstex pharmaceuticalsLate development oncologyEuropean association of urology

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

/PRNewswire/ Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of.

United kingdomUnited statesSan antonioAnia diantonioIndianj urolJoseph jacobPrnewswire johnsonClin urolJanssen research developmentAmerican cancer societyEuropean association of urologyEuropean society for medical oncologyBladder cancer advocacy networkDrug administrationNone of janssen research developmentExchange commission